Germline BRCA1 mutations increase prostate cancer risk.

Area of Science:

• Genetics
• Oncology
• Mens Health

Background:

• Prostate cancer (PrCa) aetiology is poorly understood, with family history being a significant risk factor.
• Previous studies suggested an increased PrCa risk in male BRCA1 mutation carriers, but this remained controversial.
• This study aimed to clarify the role of germline BRCA1 mutations in PrCa predisposition.

Purpose of the Study:

• To evaluate the association between germline BRCA1 mutations and prostate cancer risk in a large UK population.
• To investigate the potential impact of BRCA1 mutations on PrCa predisposition.

Main Methods:

• Screened 913 male PrCa cases (aged 36–86) for germline BRCA1 mutations using Sanger sequencing.
• Analyzed the entire coding region of the BRCA1 gene.
• Utilized multiplex ligation-dependent probe amplification to detect large rearrangements in 460 cases.

Main Results:

• Identified 4 deleterious BRCA1 mutations and 45 unclassified variants.
• Deleterious BRCA1 mutations were found in 0.45% of cases, with carriers diagnosed at ages 65 and 69.
• These mutations confer an estimated 3.75-fold relative risk of PrCa, with an 8.6% cumulative risk by age 65.

Conclusions:

• Evidence suggests an increased risk of prostate cancer in men with germline BRCA1 mutations.
• These findings have potential implications for PrCa screening strategies and targeted therapies.